Illuminating the Future: Opus Genetics Secures $20M to Transform Ophthalmic Gene Therapy

Opus Genetics, a trailblazer in the field of ophthalmic biopharmaceutical innovation, is proud to announce a significant funding milestone, raising $20,000,000 in our latest financing round. This new capital injection marks a pivotal moment for our company as we build on the exciting foundations laid by Ocuphire Pharma, Inc. and our own commitment to developing transformative therapies. By combining the pioneering spirit and expertise of both former entities under the united Opus Genetics banner (Nasdaq: IRD), we stand at the forefront of clinical-stage development, focused on advancing gene therapies that target inherited retinal diseases (IRDs) and other retinal and refractive disorders. The funds will be strategically deployed to accelerate our research and development efforts, enhance clinical trial capabilities, and expand our state-of-the-art biopharmaceutical infrastructure. With an unwavering mission to innovate, improve efficiency, and ensure sustainability in our processes, we are poised to bring groundbreaking treatments from the laboratory to the clinic. These therapies are designed to not only halt the progression of debilitating retinal conditions but also restore vision and improve quality of life for patients whose options have been limited until now. Our robust pipeline reflects a deep commitment to scientific excellence and patient-centric solutions, and this funding injection further reinforces our dedication to transforming the landscape of ophthalmic care. As we continue to strengthen our clinical and operational capabilities, Opus Genetics remains focused on forging new paths in gene therapy, ultimately creating a brighter future for millions impacted by retinal diseases worldwide.